IMPROVED TOLERABILITY OF FELODIPINE COMPARED WITH AMLODIPINE IN ELDERLY HYPERTENSIVES: A RANDOMISED,DOUBLE-BLIND STUDY IN 535 PATIENTS,FOCUSING ON VASODILATORY ADVERSE EVENTS |
| |
| Authors: | RM Schaefer MD PM Aldons FRACP ED Burgess MD R Tilvis MD X Girerd MD GP Singh FRACP L Rehn MD TO Morgan MD FRACP International Study Group |
| |
| Institution: | 1. University of Munster, Germany;2. Brisbane, Australia;3. Calgary, Canada;4. Department of Medicine, University of Helsinki, Finland;5. Dept d'Hypertension artérielle, Hôpital Broussais, Paris, France;6. Geriatric Unit, North Shore Hospital, Auckland, New Zealand;7. Essen, Germany;8. Department of Physiology, Melbourne University, Australia |
| |
| Abstract: | SUMMARY The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine. A total of 535 patients over 65 years old with a sitting diastolic blood pressure of 90-115 mmHg and/or systolic blood pressure 160-220 mmHg, were recruited at 46 centres worldwide. Patients were randomised to felodipine ER 2.5 mg or amlodipine 5 mg. If blood pressure was >160/90 mmHg after three or six weeks, felodipine ER was increased to 5 and 10 mg and amlodipine to 10 mg. After nine weeks, average doses of felodipine ER and amlodipine were 5.5 mg and 7.3 mg, respectively. Newly occurring vasodilatory adverse events were reported by 32% of felodipine ER patients and 43% of amlodipine patients (p=0.007). Both treatments effectively reduced blood pressure 24 hours post-dose. Using a low starting dose and individual titration, felodipine ER achieves good control of blood pressure with few vasodilatory side-effects. |
| |
| Keywords: | |
|
|
